News

Filter

Current filters:

Rhucin

Pharming extends Ruconest deal with SOBI

16-08-2011

Netherlands-based biotech firm Pharming Group NV (Euronext: PHARM) has extended its existing agreement…

BiotechnologyEuropeLicensingPharmaceuticalPharmingRare diseasesRest of the WorldRhucinRuconestSwedish Orphan Biovitrum

Pharming’s Ruconest efficacy backed in new trial

24-05-2011

Netherlands-based biotechnology firm Pharming Group (NYSE Euronext: PHARM) says that new clinical data…

BiotechnologyPharmingRare diseasesResearchRhucinRuconest

Pharming licenses North American rights to HAE drug Rhucin to Santarus for upfront $15 million

14-09-2010

Netherlands-based biotech firm Pharming Group NV (Euronext: PHARM) says it has entered into an agreement…

BiotechnologyLicensingPharmaceuticalPharmingRare diseasesRhucinSantarus

Pharming plans to file Rhucin BLA with US FDA by end 2010

31-08-2010

Netherlands-based biotechnology company Pharming Group NV (NYSE Euronext: PHARM) says that it intends…

BiotechnologyCardio-vascularFinancialLicensingPharmaceuticalPharmingRegulationRhucinSwedish Orphan Biovitrum

Dutch firm Pharming initiates DNage divestment, to focus on Rhucin

18-05-2010

Netherlands-based biotechnology company Pharming Group NV said yesterday that it has initiated the process…

BiotechnologyCardio-vascularDNageFinancialImmunologicalsMergers & AcquisitionsPharmaceuticalPharmingResearchRhucin

Back to top